What is Radformation?
Radformation is dedicated to revolutionizing cancer care by providing safer, smarter radiation treatment plans, aiming to expedite patient treatment timelines. The company's core objective is to democratize high-quality cancer care, making it accessible globally by automating and standardizing the treatment planning workflow. By tackling the complexities of healthcare automation, Radformation seeks to mitigate the increasing global impact of cancer, which claims approximately 10 million lives annually. Their commitment lies in delivering robust, high-quality solutions that ensure standardized care for all individuals in need.
How much funding has Radformation raised?
Radformation has raised a total of $2.6M across 3 funding rounds:
Private Equity
$663K
Angel/Seed
$1.6M
Debt
$350K
Private Equity (2017): $663K, investors not publicly disclosed
Angel/Seed (2018): $1.6M led by Brooklyn Bridge Ventures
Debt (2020): $350K supported by PPP
Key Investors in Radformation
Brooklyn Bridge Ventures
Brooklyn Bridge Ventures is a venture capital firm that typically invests in early-stage companies. Their focus on seed-stage investments suggests a strategic interest in Radformation's foundational growth and innovative approach to healthcare technology.
PPP
Public-Private Partnership
What's next for Radformation?
With the recent enterprise-level funding, Radformation is poised for significant expansion and further development of its automated radiation treatment planning solutions. The company's strategic focus will likely involve scaling its operations to reach a broader patient demographic and enhancing its technological capabilities to address the evolving challenges in oncology. Continued investment in research and development, coupled with strategic partnerships, will be crucial for Radformation to solidify its position as a leader in healthcare automation and achieve its goal of reducing cancer's global burden.
See full Radformation company page
